Developing AntiCancer Drugs from Plant Extracts

The agreement signed protects the rights of all the parties involved, including the countries of origin of the source plants.

The [U.S.] National Cancer Institute (Bethesda, MD, USA) will provide 36 anti-solid tumor plant extracts from its Natural Products Repository. Unigen Pharmaceuticals, Inc. (Broomfield, CO, USA) will analyze these samples utilizing its PhytoLogix technology platform to carry out high-throughput purification and identification. Isolated compounds will be transferred to the Josephine Ford Cancer Center (Detroit, MI, USA) for further screening against breast, lung, and colon tumor cells.

"This collaboration is quite unique,” said Dr. Qi Jia, vice president of scientific affairs at Unigen, "because it brings together NCI's natural product diversity, Unigen's high-throughput technologies, and the Ford Cancer Center's novel solid tumor selective discovery platform into one integrated effort to conquer the insidious solid-tumor diseases afflicting millions of people around the world.”




Related Links:
Unigen Pharmaceuticals
Josephine Ford Cancer Center
National Cancer Institute